Patient preferences for infusion systems
Part of Immune system & allergy clinical trials.
This study asks people like you which infusion system they prefer for their immunoglobulin therapy. By sharing your experience, you help improve future care choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary or secondary immunodeficiency or chronic inflammatory demyelinating polyneuropathy.
- You are currently receiving immunoglobulin replacement therapy.
- You have used an electronic subcutaneous immunoglobulin infusion system for at least 3 months.
- You are 18 years or older.
- You are not participating in another clinical study at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
Hear when a new Primary Immunodeficiencies (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.